Learn About the Positive Results in Recent Phase 1/2 Clinical Trial
Orcosa
  • Technology
    Technology
    • RITe™ Platform

      Our breakthrough, proprietary technology platform engineered to enhance drug absorption

    • Capabilities

      End-to-end, in-house control of formulation, development, and manufacturing capabilities

  • Research
    Research
    • ORAVEXX™ Research + Development

      Our proprietary cannabinoid composition for the management of pain and inflammation

    • Research Partners

      Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials

    • About Cannabidiol

      Learn more about cannabidiol from the medical community and regulators

  • Company
    Company
    • About Us

      We are modernizing the way medicines are taken

    • Our Team

      Experts in drug development and delivery, manufacturing, and commercialization

  • News
    News
    • In the News

      Recent media coverage regarding Orcosa

    • Press Releases and Blog Posts

      Company news and announcements

  • Careers
    Careers
Contact

Press Releases
and Blog Posts

Jul 22, 2022
Statement on Enrollment of First Patient in NYU Langone Health’s Phase 2 Clinical Trial Utilizing ORAVAEXX™
Jul 15, 2022
Orcosa Appoints Andrew C. von Eschenbach, M.D. and Former Commissioner of the FDA, as Senior Advisor
Mar 25, 2022
Orcosa Comments on Positive Results of NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORAVEXX™
Dec 27, 2021
Statement on Final Patient Dosing in NYU Langone Health’s Phase 1/2 Clinical Trial Utilizing ORAVEXX™
1 2 Next »
  • Technology
  • Research
  • Company
  • Careers
Orcosa
© 2022 Orcosa. All rights reserved.
  • Privacy Policy
  • Accessibility Statement